naquotinib
Phase 1Terminated 2 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-small Cell Lung Cancer (NSCLC)
Conditions
Non-small Cell Lung Cancer (NSCLC), Epidermal Growth Factor Receptor (EGFR) Mutations
Trial Timeline
Mar 24, 2017 → Jun 19, 2017
NCT ID
NCT03082300About naquotinib
naquotinib is a phase 1 stage product being developed by Astellas Pharma for Non-small Cell Lung Cancer (NSCLC). The current trial status is terminated. This product is registered under clinical trial identifier NCT03082300. Target conditions include Non-small Cell Lung Cancer (NSCLC), Epidermal Growth Factor Receptor (EGFR) Mutations.
What happened to similar drugs?
20 of 20 similar drugs in Non-small Cell Lung Cancer (NSCLC) were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03082300 | Phase 1 | Terminated |
Competing Products
20 competing products in Non-small Cell Lung Cancer (NSCLC)